MedTrace Logo

An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease

NCT01013610 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2011-03-15

No results posted yet for this study

Summary

To evaluate the safety, tolerability, multiple dose plasma pharmacokinetics (PK) of LNK-754 in male and female elderly volunteers after dosing with LNK-754 for 7 days and in subjects with mild Alzheimer's Disease after dosing with LNK-754 for 28 days.

Conditions

  • Mild Alzheimer's Disease

Interventions

DRUG

LNK-754

Escalating dose

DRUG

Placebo

Escalating dose

Sponsors & Collaborators

  • Link Medicine Corporation

    lead INDUSTRY

Principal Investigators

  • Robert Riesenberg, MD · Atlanta Center for Medical Research

  • Abel Murillo, MD · Elite Research Institute

  • Craig T. Curtis, MD · Compass Research

  • Kyle Patrick, D.O. · Dedicated Phase I

  • Maxwell Axler, MD · Clinical Trial Network

  • Ricky S. Mofsen, D.O. · St. Louis Clinical Trials, LC

  • Armen Goenjian, MD · Collaborative Neuroscience Network

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01013610 on ClinicalTrials.gov